GILD34:BVMF
Gilead Sciences Inc BDR
65,81 R$
0,00%
(0,00) 1 Д
16. окт, 16:56:00 GMT-3 · BRL
search
Сви симболи
| Симбол | Цена | Промена | % промене |
|---|
insights_autoГенеришу се најзначајнији увиди за GILD34...
Отвори
66,36 R$
Високо
66,41 R$
Ниско
65,81 R$
Трж. капитализација
193,67 млрд.
Прос. количина
261,00
Количина
1,78 хиљ.
Највиша у 52 недеље
67,38 R$
Најнижа у 52 недеље
51,33 R$
Акцијски капитал
1,24 млрд.
Бр. запослених
17 хиљ.
Отвори
66,36 R$
Високо
66,41 R$
Ниско
65,81 R$
Трж. капитализација
193,67 млрд.
Прос. количина
261,00
Количина
1,78 хиљ.
Највиша у 52 недеље
67,38 R$
Најнижа у 52 недеље
51,33 R$
Акцијски капитал
1,24 млрд.
Бр. запослених
17 хиљ.
Вести
Из веб-извора и од партнера за вести
Simply Wall Street
·
пре 17 сати
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
пре 22 сата
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Investing.com Canada
·
пре 1 дана
Form 4 Gilead Sciences Inc: Johanna Mercier (Chief Comm & Corp Aff Officer) For: 15 October
Investing.com Nigeria
·
пре 1 дана
Gilead chief comm & corp aff officer sells $468,660 in GILD shares
Профил
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences Inc BDR – основни подаци
Главни извршни директорДанијел О'деј
Запослени17 хиљ.
Основано22. 6. 1987.
СедиштеФостер Сити, Калифорнија, Сједињене Државе
Сектор-
Веб-сајтgilead.com